Oil Marketing Stocks Rally as Brent Crude Dips Below 98 Fuel Prices Rise for Fourth Time US Prioritizes American AI Integration in Asia Following TrumpXi Summit Fifth District Bancorp Director Linda Sins Reports Minimal Share Sale Tulsi Gabbard Resigns as US Director of National Intelligence Leadership Transition Could Influence National Security Policy Trump Pressures Fed for Independence Recalls Past RateCut Demands Dell Technologies Leads AI Server Rally with 15 Surge HPE and Super Micro Also Advance on AI Capex Momentum RLI Q1 2026 Earnings EPS Beats by Nearly 5 as Underwriting Disciplines Deliver RPAY Q1 2026 Earnings NonGAAP EPS Beats Estimates Shares Edge Higher IRIX Q1 2026 Earnings NarrowerthanExpected Loss Signals Operational Discipline FRPH Q4 2024 Earnings EPS of 009 Reported Stock Declines Slightly CNXN Q1 2026 Earnings EPS Surges Past Estimates with 2478 Surprise 908 Devices Q1 2026 Earnings EPS Misses Estimates Significantly Despite Stock Gain DBA Centerspace CSR Slips 05 as Stock Tests Key Support Levels Aurora Cannabis ACB Slips 28 as Shares Test Key Support Zone Siebert Financial Corp SIEB Surges 319 as Bullish Momentum Builds Near Key Resistance Enphase Energy ENPH Holds Near Key Support After Slight Decline Advance Auto Parts AAP Drops Nearly 5 Support Levels and Potential Scenarios to Watch Singapore Lifts 2026 Export Growth Forecast on Surge in AIDriven Demand First Citizens BancShares FCNCA Q1 2026 Earnings Strong EPS Beat Highlights Resilient Core Operations Lionheart Holdings Unit CUBWU Holds Steady Near Support Quiet Trading Signals Consolidation SCCO Q1 2026 Earnings Earnings Beat Amid Copper Price Strength PONY Q1 2026 Earnings Narrower Loss Per ADS Drives Positive Investor Sentiment AlTi Global Inc ALTI Q1 2026 Earnings EPS Beats Estimates by 307 Amid Market Weakness Sachem Capital Corp 800 Notes due 2027 SCCG Q4 2025 Earnings Modest EPS Beat Amid Broader Market Caution DOX Q1 2026 Earnings EPS Slightly Misses Estimates Stock Edges Lower SRFM Q1 2026 Earnings EPS Beats Estimate by 263 as Revenue Remains Undisclosed Protara Therapeutics TARA Q1 2026 Earnings Narrower Loss Beats Street Estimates on Cost Management